Skip to main content
Press Release

Ready Pharmacy agrees to $400,000 settlement relating to Controlled Substances Act claims

For Immediate Release
U.S. Attorney's Office, District of New Mexico

ALBUQERQUE, N.M. – Fred J. Federici, U.S. Attorney for the District of New Mexico, has announced that Ready Pharmacy has agreed to a $400,000 settlement relating to civil claims brought by the Department of Justice on behalf of the U.S. Drug Enforcement Administration’s (DEA) El Paso Division Regulatory Diversion Group.

Ready Pharmacy, which is no longer in operation, was registered with the DEA as a retail pharmacy and authorized to dispense controlled substances customers pursuant to the provisions of the Controlled Substances Act (CSA).

At issues in the civil claim was the failure to account for over 26,000 missing dosage units of controlled substances on March 15, 2016. Also, during an on-site inspection, controlled substances were discovered unsafeguarded and not properly stored.

By the terms of the settlement, the owners of Ready Pharmacy have agreed to pay $400,000 and the government will release Ready Pharmacy from any further civil or administrative monetary claims the United States has for the covered conduct under the CSA.

“In reaching this agreement, we emphasize the necessity of adherence to the Controlled Substances Act,” said U.S. Attorney Federici. “It is our duty to ensure that the conditions and responsibilities upon which that authority is based are upheld and that its limits are not abused by retail pharmacies registered with the DEA.”

“The Controlled Substances Act sets forth clear rules for all entities that dispense controlled substances,” said Greg Millard, Acting Special Agent in Charge of the Drug Enforcement Administration’s El Paso Division. “Our office will continue to use its oversight responsibilities to ensure registrants comply with the law.”

Ready Pharmacy must pay an initial amount of $50,000 within 30 days of the settlement date and must pay the remaining $350,000 over a five-year period.

Assistant U.S. Attorney Ruth F. Keegan represented the United States in the settlement agreement.

Updated February 1, 2022

Prescription Drugs
Press Release Number: 22-19